Guardant Health, Inc. Form 4 Filings

Guardant Health, Inc. (GH) reported that Co-Chief Executive Officer and director AmirAli Talasaz, through indirect ownership by the Talasaz Family Foundation, sold a total of 37,500 shares of common stock on August 21, 2026 in open-market or private transactions. The sales occurred in three weighted-average price tranches between $167.81 and $170.50 per share. The transactions were not reported as made under a Rule 10b5-1 trading plan.

Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and settlement of equity awards. On August 21, 2026, 264 Restricted Stock Units were converted into 264 shares of Common Stock at $0.00 per share. Following these transactions, he holds 10,010 Common shares and 6,864 RSUs, all as direct ownership. The RSUs were from a November 8, 2024 grant that vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the next three years.

Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported the vesting and conversion of restricted stock units into common stock. On August 17, 2026, 232 restricted stock units were converted into 232 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he held 4,788 shares of common stock directly and 5,337 restricted stock units, which continue to vest under an award granted on July 17, 2024.

Guardant Health, Inc. (GH) director Tariq Musa reported a combination of RSU vesting and share sales. On August 15, 2026, 250 Restricted Stock Units were converted into 250 shares of common stock, increasing direct holdings to 1,749 shares. On August 17, 2026, he sold 116 common shares at $156.45 per share in an open-market or private transaction. The RSU award was granted on March 6, 2023 and vests over four years, with 25% vested March 15, 2024 and the remaining 75% vesting monthly over the following three years. The filing indicates these transactions were effected under a Rule 10b5-1 trading plan.

Guardant Health, Inc. executive Terilyn J. Monroe, Chief People Officer, exercised stock options covering 46,300 shares of common stock on 2026-08-12 (32,288 shares at an exercise price of $20.14 and 14,012 shares at $28.61). She then sold 46,300 common shares in multiple open-market or private transactions at weighted average prices ranging from $162.80 to $168.02. The exercised options were from awards granted on February 26, 2024 and November 8, 2024, each vesting over three years with 33% vesting after roughly one year and the remaining 67% in equal monthly installments over the next two years. The filing does not affirm trading under a Rule 10b5-1 plan.

Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy reported two bona fide gift transactions involving common stock on 2026-08-11. A total of 35,000 shares of Guardant Health common stock were transferred from the Helmy A. Eltoukhy Revocable Trust, reducing that trust’s indirect holdings to 1,995,934 shares. On the same date, 35,000 shares were recorded as acquired as indirect holdings of The Eltoukhy Foundation. A footnote states that these entries reflect changes in form of ownership from the revocable trust to The Eltoukhy Foundation, indicating an internal re-titling of shares rather than an open-market purchase or sale.

Guardant Health, Inc. director and Co-Chief Executive Officer AmirAli Talasaz reported internal transfers of common stock interests involving family entities. On 2026-08-10, 75,000 shares were transferred as a bona fide gift from the Talasaz and Eskandari 2017 Family Trust, reducing that indirect holding to 1,824,351 shares, and 75,000 shares were received by The Talasaz Family Foundation, which now holds 75,000 shares. A footnote states these transactions reflect changes in form of ownership between the trust and the foundation.

Guardant Health, Inc. executive John G. Saia, Chief Legal Officer, reported a bona fide gift of 800 shares of common stock on 2026-08-10. The gift reflects a change in form of ownership due to a transfer to a donor-advised fund within the Saia Family Foundation. Following this charitable transfer, Saia directly holds 38,991 shares of Guardant Health common stock.

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported option exercises and share sales on August 10, 2026. He exercised stock options covering 63,605 shares of common stock, including 35,412 shares at an exercise price of $110.49 per share from an award granted August 3, 2021, which is now fully vested, and 28,193 shares at an exercise price of $28.37 per share from an award granted December 13, 2023 that continues to vest over a three-year period. Freeman then sold 63,605 shares of common stock in open-market transactions at weighted average prices per share ranging from approximately $167.12 to $170.67, with the exact breakdown of shares sold at each price available upon request as noted in the footnotes.

Guardant Health director Manuel Hidalgo Medina exercised stock options for 950 shares on August 5, 2026 at an exercise price of $32.5500 per share, receiving 950 common shares. He then sold 1,700 common shares in two trades at $163.9450 and $164.6051 per share. After the exercise, he continued to hold stock options covering 12,079 shares that were granted on July 17, 2024 and vest 25% on July 17, 2025, with the remaining 75% vesting monthly over the following three years.

Guardant Health, Inc. director Ian T. Clark exercised stock options and sold shares held through a family trust. On 2026-08-04, options for 2,255 and 6,833 shares of common stock were exercised at strike prices of $91.11 and $50.57. The Thornton-Clark Family Trust then sold a total of 14,180 common shares at weighted average prices of $158.98 and $158.80, within disclosed price ranges.

Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share. Following this transaction, he directly holds 9,746 Common shares and 7,128 Restricted Stock Units. The RSU grant, awarded on November 8, 2024, vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the subsequent three years. The transaction was not marked as made under a Rule 10b5-1 trading plan, as the related checkbox was left unchecked.

Guardant Health, Inc. director Manuel Hidalgo Medina reported the vesting and settlement of 232 Restricted Stock Units into 232 shares of common stock on July 17, 2026. After these transactions he directly holds 5,306 common shares and 5,569 remaining RSUs from a four-year grant awarded July 17, 2024.

Guardant Health director Tariq Musa reported transactions in company equity. On July 15, 2026, he converted 250 Restricted Stock Units into 250 shares of common stock at no cash cost, leaving 1,999 RSUs outstanding. On July 16, he sold 116 shares of common stock in an open-market sale at $163.29 per share and held 11,182 shares afterward.

Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity tied to restricted stock units (RSUs). On 2026-07-01, several RSU awards vested and converted into a total of 7,063 shares of Guardant Health common stock at a stated price of $0.00 per share.

To cover tax obligations from this vesting, the company retained 3,707 shares at a price of $170.77 per share, according to the filing footnotes. These transactions reflect RSU vesting, derivative exercises, and tax withholding, not open-market purchases or sales.

Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity. On July 1, 2026, restricted stock units converted into a total of 4,020 shares of Common Stock, reflecting scheduled vesting of prior awards. The company retained 2,099 shares at $170.77 per share to cover Ms. Monroe’s tax withholding obligations, rather than through an open-market sale. Following these transactions, she continues to hold both common shares and unvested restricted stock units as part of her compensation.

Guardant Health, Inc. Chief Information Officer Kumud Kalia reported routine equity compensation activity. On 2026-07-01, several batches of restricted stock units vested and were converted into a total of 6,046 shares of common stock at a conversion price of $0.00 per share.

To cover associated tax obligations from this vesting, 3,066 shares of common stock were withheld by the company at a value of $170.77 per share, as described in the footnotes. These transactions reflect compensation-related vesting and tax withholding rather than open-market buying or selling.

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported compensation-related equity activity involving restricted stock units. On July 1, 2026, RSU awards vested and were converted into a total of 7,414 shares of common stock, reflecting derivative exercises rather than open-market purchases.

To cover tax obligations arising from this vesting, 3,141 shares of common stock were retained by the company at a value of $170.77 per share, as noted in the footnotes. The transactions do not include any open-market buying or selling, and are characterized as routine equity compensation and tax withholding events.

Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, several restricted stock unit awards converted into common stock, reflected as multiple exercise transactions.

In connection with the vesting, 4,318 shares of common stock were retained by Guardant Health at $170.77 per share to cover her tax withholding obligations, as described in the footnotes. Following these transactions, Chudova directly held 78,373 shares of Guardant Health common stock.

Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity involving restricted stock units that vested into common stock. On July 1, 2026, RSU conversions delivered 7,278 shares of common stock, while 3,914 shares were withheld at $170.77 per share to cover tax obligations, rather than sold in the open market.

Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy, through the Helmy A. Eltoukhy Revocable Trust, reported routine equity compensation activity involving restricted stock units and related tax withholding.

On June 30 and July 1, 2026, a total of 36,529 restricted stock units were converted into an equal number of shares of common stock at a conversion price of $0.00 per share. To satisfy tax withholding obligations tied to these vestings, 18,514 shares of common stock were retained by the company at prices of $150.03 and $170.77 per share, as noted in the footnotes. These F-code dispositions reflect payment of tax liabilities rather than open-market sales.

Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units. On June 30 and July 1, 2026, a total of 36,529 restricted stock units converted into common stock through derivative exercises, reflecting scheduled vesting.

Across the same dates, 18,514 common shares were withheld and retained by the company at prices of $150.03 and $170.77 per share to cover tax liabilities associated with these vesting events. The transactions occurred through the Talasaz and Eskandari 2017 Family Trust and do not involve any open-market purchases or sales.

Guardant Health director Steve E. Krognes reported an exercise of restricted stock units that delivered 155 shares of common stock on June 30, 2026. These RSUs were from an award granted on August 9, 2022, which vested 25% on June 30, 2023 and the remaining 75% over the following three years.

After this derivative exercise, Krognes directly holds 14,580 shares of Guardant Health common stock. This Form 4 reflects a compensation-related vesting and conversion of equity awards, with no open-market buying or selling reported in this filing.

Guardant Health Chief Information Officer Kumud Kalia reported small, offsetting insider trades in company common stock. On June 10 and June 15, Kalia executed open-market sales totaling 1,200 shares at prices around $130–$131 per share and an open-market purchase of 600 shares at about $130.76 per share.

After these transactions, Kalia directly holds 40,814 shares of Guardant Health common stock. A footnote states that, based on these trades, the company identified recoverable Section 16(b) short-swing profits of $192, which Kalia has paid back to the company.

Guardant Health, Inc. co-CEO AmirAli Talasaz reported a combination of stock option exercises and share sales tied to the Talasaz and Eskandari 2017 Family Trust. On June 26 and June 29, 2026, the trust sold an aggregate 260,000 shares of common stock in open-market transactions at weighted-average prices around $150–$153 per share, executed across multiple price ranges.

On the same dates, stock options to acquire a total of 254,832 shares of common stock were exercised at a $4.18 per-share exercise price, converting derivative awards into common shares. The common stock and options are reported as held directly or indirectly, with a significant portion attributed to the Talasaz and Eskandari 2017 Family Trust.

Guardant Health director Tariq Musa sold 1,951 shares of Common Stock in an open-market transaction. The shares were sold at an average price of $131.16 per share. After this sale, Musa directly holds 11,048 Guardant Health shares, indicating he retains a significant ongoing equity position in the company.

Guardant Health, Inc. director Myrtle S. Potter reported an open-market sale of Common Stock. She sold 1,556 shares on June 22, 2026 at an average price of $131.16 per share. After this transaction, she directly holds 20,971 Guardant Health shares.

Guardant Health director Roberto Mignone reported routine equity compensation activity, exercising restricted stock units (RSUs) into common shares. On May 21, 2026 and June 21, 2026, RSU conversions of 264 shares each delivered a total of 528 common shares at a stated price of $0.00 per share.

After these transactions, Mignone directly held 9,482 shares of Guardant Health common stock and 7,392 RSUs. Footnotes explain that the RSU award was granted on November 8, 2024 and vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.

Guardant Health director Tariq Musa reported routine equity compensation activity. On June 17, 2026, he exercised 4,203 Restricted Stock Units into the same number of common shares following full vesting tied to the 2026 Annual Meeting of Stockholders.

He also received a new grant of 2,711 Restricted Stock Units that will vest in full on the one-year anniversary of the grant date, June 17, 2026, or on the date of Guardant Health’s next annual meeting of stockholders, whichever is earlier. Following these transactions, Musa directly holds 12,999 shares of common stock and 2,711 Restricted Stock Units, with no shares sold.

Guardant Health director Myrtle S. Potter reported routine equity compensation activity. On June 17, 2026, she exercised 4,203 Restricted Stock Units, acquiring the same number of common shares and bringing her direct common stock holdings to 22,527 shares. A prior restricted stock unit award vested in full on the 2026 Annual Meeting date. She also received a new grant of 2,711 Restricted Stock Units, which will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.

Guardant Health director Roberto Mignone reported routine equity compensation activity. On June 17, 2026, he exercised restricted stock units covering 4,203 shares of Common Stock, bringing his direct Common Stock holdings to 8,954 shares after the transaction.

On the same date, he received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of Common Stock. According to the footnotes, the RSU award that generated the 4,203 shares vested in full on the date of the 2026 Annual Meeting of Stockholders, while the new 2,711-unit award will vest in full on the earlier of the one-year anniversary of its June 17, 2026 grant date or the Company’s next annual meeting of stockholders.

Guardant Health director Steve E. Krognes reported equity compensation activity. On June 17, 2026, 4,203 Restricted Stock Units fully vested in connection with the company’s 2026 Annual Meeting of Stockholders and were converted into an equal number of shares of common stock.

Following this derivative exercise, Krognes held 14,425 shares of Guardant Health common stock directly. On the same date, he also received a new grant of 2,711 Restricted Stock Units, each representing a right to receive one share of common stock that will vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting.

Guardant Health, Inc. director Meghan V. Joyce reported the vesting and settlement of a restricted stock unit award into common stock. On June 17, 2026, coinciding with the company’s 2026 Annual Meeting of Stockholders, 4,203 restricted stock units converted into 4,203 shares of common stock at no exercise price. Following this compensation-related transaction, Joyce directly holds 15,386 shares of Guardant Health common stock, and no open-market purchases or sales were reported in this filing.

Guardant Health director Manuel Hidalgo Medina reported compensation-related equity activity on June 17, 2026. He exercised vested restricted stock units to acquire 4,435 shares of Common Stock at a conversion price of $0.00 per share and received a new grant of 2,711 restricted stock units. Following these transactions, one reported line shows direct ownership of 5,074 Common Stock shares and 2,711 restricted stock units, reflecting routine vesting and grants rather than open-market trading.

Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity. On June 17, 2026, Gadde exercised restricted stock units covering 4,203 shares of Common Stock, increasing direct holdings to 28,517 shares. On the same date, Gadde also received a new award of 2,711 restricted stock units that will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.

Guardant Health director Ian T. Clark reported equity compensation activity tied to the 2026 Annual Meeting of Stockholders. A previously granted restricted stock unit (RSU) award vested in full on June 17, 2026 and was exercised into 5,092 shares of common stock, bringing indirect holdings in a family trust to 8,067 shares.

Clark also received a new grant of 2,711 RSUs on June 17, 2026. These RSUs convert into the same number of common shares and are scheduled to vest in full on the one-year anniversary of the grant date or on the date of Guardant Health’s next annual stockholder meeting, whichever occurs earlier. All reported transactions are acquisitions related to awards rather than open-market buying or selling.

Azar Alex M II reported acquisition or exercise transactions in this Form 4 filing.

Guardant Health director Azar Alex M II received a grant of 2,711 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of common stock for no cash payment. The award vests in full on June 17, 2026, the one-year anniversary of the grant date, or on the date of Guardant Health’s next annual meeting of stockholders, whichever occurs earlier. Following this Form 4 transaction, Azar holds 2,711 RSUs directly.

Guardant Health Chief Information Officer Kumud Kalia reported routine stock-based compensation activity. On June 15, 2026, 638 restricted stock units converted into common shares, while 314 shares were withheld by the company to cover tax obligations. After these transactions, Kalia directly holds 41,414 common shares.

Guardant Health director Tariq Musa reported a small mix of stock transactions involving company shares. On June 15, 2026, a restricted stock unit (RSU) award converted into 250 shares of common stock at a stated price of $0.00 per share, reflecting vesting of previously granted equity compensation.

The same RSU award was originally granted on March 6, 2023 and vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over three years. On June 16, 2026, Musa executed an open-market sale of 116 shares of common stock at an average price of $130.19 per share. Following these transactions, he holds 8,796 shares of Guardant Health common stock directly.

Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity on June 15, 2026. He exercised 1,020 restricted stock units into common shares, then had 535 of those shares withheld by the company at $129.82 per share to cover tax obligations, with no open-market sale. After these transactions, Saia directly holds 36,435 Guardant Health shares. The RSU award was granted on June 9, 2023 and vests over three years, with 33% vesting on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported routine equity compensation activity involving restricted stock units and common stock. On June 15, 2026, 1,402 restricted stock units were converted into an equal number of common shares as part of a previously granted award that vested over a three-year period.

To cover related tax obligations on this vesting, the company retained 594 common shares at a price of $129.82 per share, a non-market tax-withholding disposition rather than an open-market sale. Following these transactions, Freeman directly held 61,101 common shares of Guardant Health.

Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity. On June 15, 2026, 2,039 Restricted Stock Units were converted into an equal number of shares of common stock, reflecting the vesting schedule of an award granted on June 9, 2023.

On the same date, 1,096 shares of common stock were withheld by the company to cover Mr. Bell’s tax withholding obligations tied to this vesting, with the shares valued at $129.82 each. After these transactions, Mr. Bell directly owned 48,452 shares of Guardant Health common stock.

Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 3,418 shares of Common Stock on June 11, 2026 at an average price of $130.2386 per share. After this transaction, Kalia directly holds 41,090 shares, indicating he retains a substantial ongoing equity stake.

Guardant Health, Inc. Chief Information Officer Kumud Kalia reported an open-market sale of 5,000 shares of Common Stock. The shares were sold at a price of $130.406 per share. After this transaction, Kalia directly owns 44,508 shares, indicating a remaining substantial equity position.

Guardant Health, Inc. Co-Chief Executive Officer Helmy Eltoukhy reported a series of open-market sales of the company’s common stock on June 5, 2026. Through the Helmy A. Eltoukhy Revocable Trust, he sold a total of 100,000 shares in seven transactions at weighted average prices between about $124.95 and $132.55 per share. Following these sales, the trust continues to hold approximately 2,012,919 shares of Guardant Health common stock indirectly attributed to Eltoukhy.

Guardant Health, Inc. Chief Financial Officer Michael Brian Bell sold 2,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $128.6203 per share. Following this sale, he directly holds 47,509 shares of Guardant Health common stock.

The footnote explains that the sale occurred through multiple trades at prices ranging from $128.620 to $128.955 per share, and detailed trade-level information is available upon request.

Guardant Health director Steve E. Krognes sold shares in an open-market transaction. He sold 9,294 shares of Guardant Health common stock on June 4, 2026 at a weighted average price of $132.5072 per share, in multiple trades priced between $132.50 and $132.71. After this sale, he directly owns 10,222 Guardant Health shares.

Guardant Health, Inc. director Meghan V. Joyce reported option exercises and related share sales. On June 3, 2026, she exercised stock options to acquire a total of 10,000 shares of Guardant Health common stock at exercise prices of $38.005 and $38.420 per share.

On the same date, she executed open-market sales totaling 10,000 shares of common stock in multiple price tranches, at weighted average prices reported around the high $120s per share. Following these transactions, she directly holds 11,183 shares of Guardant Health common stock, and the exercised option positions have been fully converted into shares.

Guardant Health, Inc. director Steve E. Krognes reported a routine equity compensation event involving 154 shares. He exercised restricted stock units into 154 shares of Common Stock, classified as a derivative exercise rather than an open-market purchase or sale. Following this transaction, he holds 19,516 shares of Common Stock directly and 155 Restricted Stock Units.

The RSUs come from an award granted on August 9, 2022 that vested 25% of the shares on June 30, 2023, with the remaining 75% vesting in substantially equal monthly installments over three years. No shares were sold, gifted, or withheld for taxes in this filing.